The company said increased volumes plus the requirements of Food and Drug Administration (FDA) good manufacturing practices (GMPs), prompted the move, but the company said it would still employ third-party testers in specialty cases.
“This investment allows RPI to process a wider array of ingredients more rapidly – speeding the time from ingredient receipt on our dock and placement in quarantine – to release for production and processing. The new infrastructure also decreases the wait time from completion of production to release for shipment,” said RPI vice president of marketing, Kenn Israel, in a statement.
He said the lab was also greener as it used reduced amounts of solvents via four new Ultra Performance Liquid Chromatographs (UPLC) machines that are the centre piece of the renovation. They are able to process samples more quickly and use less of the solvent most commonly used in LC analysis – acetonitrile.
Other new additions are High Performance Liquid Chromatograph (HPLC) machines, a High Performance Thin Layer Chromatography (HPTLC) lab, additional Gas Chromatography resources, and an expanded microbiological lab.
RPI president and founder, Tuong Nguyen, said: “The new FDA rules raised the bar on quality making manufacturers accountable under federal law for identity, purity, and potency of ingredients…RPI is committed to our total quality program and we will continue to invest in systems and personnel to support our goal of providing the industry with the most effective contract manufacturing and private label services available.”